{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:32:37Z","timestamp":1778110357393,"version":"3.51.4"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/nrd3050","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T09:17:21Z","timestamp":1267435041000},"page":"237-248","source":"Crossref","is-referenced-by-count":685,"title":["Protein aggregation diseases: pathogenicity and therapeutic perspectives"],"prefix":"10.1038","volume":"9","author":[{"given":"Adriano","family":"Aguzzi","sequence":"first","affiliation":[]},{"given":"Tracy","family":"O'Connor","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"BFnrd3050_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature05695","volume":"447","author":"MR Sawaya","year":"2007","unstructured":"Sawaya, M. R. et al. Atomic structures of amyloid cross-\u03b2 spines reveal varied steric zippers. Nature 447, 453\u2013457 (2007).","journal-title":"Nature"},{"key":"BFnrd3050_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF01930815","volume":"6","author":"R Virchow","year":"1853","unstructured":"Virchow, R. \u00dcber eine im Gehirn und R\u00fcckenmark des Menschen aufgefundene Substanz mit der chemischen Reaktion der Cellulose. Virchows Arch. 6, 135\u2013138 (1853) (in German).","journal-title":"Virchows Arch."},{"key":"BFnrd3050_CR3","doi-asserted-by":"publisher","first-page":"e1000199","DOI":"10.1371\/journal.pcbi.1000199","volume":"4","author":"E Monsellier","year":"2008","unstructured":"Monsellier, E., Ramazzotti, M., Taddei, N. & Chiti, F. Aggregation propensity of the human proteome. PLoS Comput. Biol. 4, e1000199 (2008).","journal-title":"PLoS Comput. Biol."},{"key":"BFnrd3050_CR4","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1210\/jc.2004-0405","volume":"89","author":"RL Hull","year":"2004","unstructured":"Hull, R. L., Westermark, G. T., Westermark, P. & Kahn, S. E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3629\u20133643 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrd3050_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1083\/jcb.200302072","volume":"161","author":"JF Berson","year":"2003","unstructured":"Berson, J. F. et al. Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J. Cell Biol. 161, 521\u2013533 (2003).","journal-title":"J. Cell Biol."},{"key":"BFnrd3050_CR6","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1111\/j.1742-4658.2005.05024.x","volume":"272","author":"P Westermark","year":"2005","unstructured":"Westermark, P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 272, 5942\u20135949 (2005).","journal-title":"FEBS J."},{"key":"BFnrd3050_CR7","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1073\/pnas.0712179105","volume":"105","author":"M Vilar","year":"2008","unstructured":"Vilar, M. et al. The fold of \u03b1-synuclein fibrils. Proc. Natl Acad. Sci. USA 105, 8637\u20138642 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","volume":"90","author":"E Scherzinger","year":"1997","unstructured":"Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549\u2013558 (1997).","journal-title":"Cell"},{"key":"BFnrd3050_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1471-4159.2007.04972.x","volume":"104","author":"I Maezawa","year":"2008","unstructured":"Maezawa, I. et al. Congo red and thioflavin-T analogs detect A\u03b2 oligomers. J. Neurochem. 104, 457\u2013468 (2008).","journal-title":"J. Neurochem."},{"key":"BFnrd3050_CR10","doi-asserted-by":"publisher","first-page":"25945","DOI":"10.1074\/jbc.274.36.25945","volume":"274","author":"DM Walsh","year":"1999","unstructured":"Walsh, D. M. et al. Amyloid \u03b2-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945\u201325952 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/15216540701283882","volume":"59","author":"ST Ferreira","year":"2007","unstructured":"Ferreira, S. T., Vieira, M. N. & De Felice, F. G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332\u2013345 (2007).","journal-title":"IUBMB Life"},{"key":"BFnrd3050_CR12","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley, H. et al. Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129\u201310140 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0002-9440(10)63388-3","volume":"165","author":"C Casas","year":"2004","unstructured":"Casas, C. et al. Massive CA1\/2 neuronal loss with intraneuronal and N-terminal truncated A\u03b242 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289\u20131300 (2004).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR14","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245\u20134249 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","volume":"120","author":"RE Tanzi","year":"2005","unstructured":"Tanzi, R. E. & Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545\u2013555 (2005).","journal-title":"Cell"},{"key":"BFnrd3050_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12035-008-8031-2","volume":"37","author":"DM Barten","year":"2008","unstructured":"Barten, D. M. & Albright, C. F. Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37, 171\u2013186 (2008).","journal-title":"Mol. Neurobiol."},{"key":"BFnrd3050_CR17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nm0908-894","volume":"14","author":"T Gura","year":"2008","unstructured":"Gura, T. Hope in Alzheimer's fight emerges from unexpected places. Nature Med. 14, 894 (2008).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1126\/science.1087348","volume":"302","author":"A Aguzzi","year":"2003","unstructured":"Aguzzi, A. & Haass, C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302, 814\u2013818 (2003).","journal-title":"Science"},{"key":"BFnrd3050_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","volume":"76","author":"HF Dovey","year":"2001","unstructured":"Dovey, H. F. et al. Functional \u03b3-secretase inhibitors reduce \u03b2-amyloid peptide levels in brain. J. Neurochem. 76, 173\u2013181 (2001).","journal-title":"J. Neurochem."},{"key":"BFnrd3050_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/jpet.104.075408","volume":"312","author":"DM Barten","year":"2005","unstructured":"Barten, D. M. et al. Dynamics of \u03b2-amyloid reductions in brain, cerebrospinal fluid, and plasma of \u03b2 -amyloid precursor protein transgenic mice treated with a \u03b3-secretase inhibitor. J. Pharmacol. Exp. Ther. 312, 635\u2013643 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3050_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1124\/jpet.104.081174","volume":"313","author":"JD Best","year":"2005","unstructured":"Best, J. D. et al. Quantitative measurement of changes in amyloid- \u03b2(40) in the rat brain and cerebrospinal fluid following treatment with the \u03b3-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J. Pharmacol. Exp. Ther. 313, 902\u2013908 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3050_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1212\/01.WNL.0000198762.41312.E1","volume":"66","author":"ER Siemers","year":"2006","unstructured":"Siemers, E. R. et al. Effects of a \u03b3-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602\u2013604 (2006).","journal-title":"Neurology"},{"key":"BFnrd3050_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/34910","volume":"391","author":"B De Strooper","year":"1998","unstructured":"De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387\u2013390 (1998). This was the first indication that presenilin 1 was crucial for \u03b3-secretase activity and might constitute a viable drug target for Alzheimer's disease therapy.","journal-title":"Nature"},{"key":"BFnrd3050_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper, B. et al. A presenilin-1-dependent \u03b3-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518\u2013522 (1999).","journal-title":"Nature"},{"key":"BFnrd3050_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/387288a0","volume":"387","author":"PC Wong","year":"1997","unstructured":"Wong, P. C. et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387, 288\u2013292 (1997).","journal-title":"Nature"},{"key":"BFnrd3050_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0092-8674(00)80244-5","volume":"89","author":"J Shen","year":"1997","unstructured":"Shen, J. et al. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89, 629\u2013639 (1997).","journal-title":"Cell"},{"key":"BFnrd3050_CR27","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1074\/jbc.M311652200","volume":"279","author":"GT Wong","year":"2004","unstructured":"Wong, G. T. et al. Chronic treatment with the \u03b3-secretase inhibitor LY-411, 575 inhibits \u03b2-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876\u201312882 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754\u2013760 (1995).","journal-title":"Nature"},{"key":"BFnrd3050_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973\u2013977 (1995).","journal-title":"Science"},{"key":"BFnrd3050_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"EI Rogaev","year":"1995","unstructured":"Rogaev, E. I. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775\u2013778 (1995).","journal-title":"Nature"},{"key":"BFnrd3050_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/383710a0","volume":"383","author":"K Duff","year":"1996","unstructured":"Duff, K. et al. Increased amyloid-\u03b242(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710\u2013713 (1996).","journal-title":"Nature"},{"key":"BFnrd3050_CR32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm1096-1146","volume":"2","author":"CA Lemere","year":"1996","unstructured":"Lemere, C. A. et al. The E280A presenilin 1 Alzheimer mutation produces increased A\u03b2 42 deposition and severe cerebellar pathology. Nature Med. 2, 1146\u20131150 (1996).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nm0197-67","volume":"3","author":"M Citron","year":"1997","unstructured":"Citron, M. et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid \u03b2-protein in both transfected cells and transgenic mice. Nature Med. 3, 67\u201372 (1997).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen, S. et al. A subset of NSAIDs lower amyloidogenic A\u03b242 independently of cyclooxygenase activity. Nature 414, 212\u2013216 (2001).","journal-title":"Nature"},{"key":"BFnrd3050_CR35","doi-asserted-by":"publisher","first-page":"41987","DOI":"10.1074\/jbc.M501368200","volume":"280","author":"PC Fraering","year":"2005","unstructured":"Fraering, P. C. et al. \u03b3-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J. Biol. Chem. 280, 41987\u201341996 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1124\/jpet.107.129007","volume":"323","author":"BP Imbimbo","year":"2007","unstructured":"Imbimbo, B. P. et al. 1-(3\u2032,4\u2032-Dichloro-2-fluoro[1,1\u2032-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel \u03b3-secretase modulator, reduces brain \u03b2-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822\u2013830 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3050_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2202-8-54","volume":"8","author":"T Kukar","year":"2007","unstructured":"Kukar, T. et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8, 54 (2007).","journal-title":"BMC Neurosci."},{"key":"BFnrd3050_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","volume":"21","author":"DR Galasko","year":"2007","unstructured":"Galasko, D. R. et al. Safety, tolerability, pharmacokinetics, and A\u03b2 levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord. 21, 292\u2013299 (2007).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrd3050_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"GK Wilcock","year":"2008","unstructured":"Wilcock, G. K. et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483\u2013493 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrd3050_CR40","unstructured":"Myriad Genetics. Press release June 30: Myriad Genetics reports results of U.S. Phase 3 trial of Flurizan\u2122 in Alzheimer's disease. Myriad Genetics website [online], (2008)."},{"key":"BFnrd3050_CR41","first-page":"721","volume":"10","author":"BP Imbimbo","year":"2009","unstructured":"Imbimbo, B. P. & Peretto, I. Semagacestat, a \u03b3-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr. Opin. Investig. Drugs 10, 721\u2013730 (2009).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd3050_CR42","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1126\/science.1160649","volume":"323","author":"A Thathiah","year":"2009","unstructured":"Thathiah, A. et al. The orphan G protein-coupled receptor 3 modulates amyloid-\u03b2 peptide generation in neurons. Science 323, 946\u2013951 (2009).","journal-title":"Science"},{"key":"BFnrd3050_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1126\/science.1171176","volume":"324","author":"L Serneels","year":"2009","unstructured":"Serneels, L. et al. \u03b3-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324, 639\u2013642 (2009).","journal-title":"Science"},{"key":"BFnrd3050_CR44","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar, R. et al. \u03b2-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735\u2013741 (1999).","journal-title":"Science"},{"key":"BFnrd3050_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/mcne.1999.0811","volume":"14","author":"I Hussain","year":"1999","unstructured":"Hussain, I. et al. Identification of a novel aspartic protease (Asp 2) as \u03b2-secretase. Mol. Cell Neurosci. 14, 419\u2013427 (1999).","journal-title":"Mol. Cell Neurosci."},{"key":"BFnrd3050_CR46","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1073\/pnas.97.4.1456","volume":"97","author":"X Lin","year":"2000","unstructured":"Lin, X. et al. Human aspartic protease memapsin 2 cleaves the \u03b2-secretase site of \u03b2-amyloid precursor protein. Proc. Natl Acad. Sci. USA 97, 1456\u20131460 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/990114","volume":"402","author":"S Sinha","year":"1999","unstructured":"Sinha, S. et al. Purification and cloning of amyloid precursor protein \u03b2-secretase from human brain. Nature 402, 537\u2013540 (1999).","journal-title":"Nature"},{"key":"BFnrd3050_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/990107","volume":"402","author":"R Yan","year":"1999","unstructured":"Yan, R. et al. Membrane-anchored aspartyl protease with Alzheimer's disease \u03b2-secretase activity. Nature 402, 533\u2013537 (1999).","journal-title":"Nature"},{"key":"BFnrd3050_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo, Y. et al. Mice deficient in BACE1, the Alzheimer's \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation. Nature Neurosci. 4, 231\u2013232 (2001). This was the first demonstration that deficiency in BACE1 abolished \u03b2-amyloid production in vivo , establishing the \u03b2-secretase as a valid drug target for Alzheimer's disease.","journal-title":"Nature Neurosci."},{"key":"BFnrd3050_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","volume":"41","author":"M Ohno","year":"2004","unstructured":"Ohno, M. et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27\u201333 (2004).","journal-title":"Neuron"},{"key":"BFnrd3050_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2006.12.008","volume":"26","author":"M Ohno","year":"2007","unstructured":"Ohno, M. et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP\/PS1 transgenic mice. Neurobiol. Dis. 26, 134\u2013145 (2007).","journal-title":"Neurobiol. Dis."},{"key":"BFnrd3050_CR52","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird, F. M. et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-\u03b2 amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693\u201311709 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR53","doi-asserted-by":"publisher","first-page":"26326","DOI":"10.1074\/jbc.M611687200","volume":"282","author":"L McConlogue","year":"2007","unstructured":"McConlogue, L. et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326\u201326334 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/156720508783954730","volume":"5","author":"AK Ghosh","year":"2008","unstructured":"Ghosh, A. K., Kumaragurubaran, N., Hong, L., Koelsh, G. & Tang, J. Memapsin 2 (\u03b2-secretase) inhibitors: drug development. Curr. Alzheimer Res. 5, 121\u2013131 (2008).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrd3050_CR55","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/nn1797","volume":"9","author":"X Hu","year":"2006","unstructured":"Hu, X. et al. Bace1 modulates myelination in the central and peripheral nervous system. Nature Neurosci. 9, 1520\u20131525 (2006).","journal-title":"Nature Neurosci."},{"key":"BFnrd3050_CR56","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ncb1602","volume":"9","author":"DY Kim","year":"2007","unstructured":"Kim, D. Y. et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nature Cell Biol. 9, 755\u2013764 (2007).","journal-title":"Nature Cell Biol."},{"key":"BFnrd3050_CR57","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.1074\/jbc.M409417200","volume":"280","author":"S Kitazume","year":"2005","unstructured":"Kitazume, S. et al. In vivo cleavage of \u03b12,6-sialyltransferase by Alzheimer \u03b2-secretase. J. Biol. Chem. 280, 8589\u20138595 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR58","doi-asserted-by":"publisher","first-page":"11982","DOI":"10.1074\/jbc.M700356200","volume":"282","author":"PH Kuhn","year":"2007","unstructured":"Kuhn, P. H. et al. Regulated intramembrane proteolysis of the interleukin-1 receptor II by \u03b1-, \u03b2-, and \u03b3-secretase. J. Biol. Chem. 282, 11982\u201311995 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR59","doi-asserted-by":"publisher","first-page":"10542","DOI":"10.1074\/jbc.M310001200","volume":"279","author":"Q Li","year":"2004","unstructured":"Li, Q. & Sudhof, T. C. Cleavage of amyloid-\u03b2 precursor protein and amyloid-\u03b2 precursor-like protein by BACE 1. J. Biol. Chem. 279, 10542\u201310550 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR60","doi-asserted-by":"publisher","first-page":"48713","DOI":"10.1074\/jbc.M303861200","volume":"278","author":"SF Lichtenthaler","year":"2003","unstructured":"Lichtenthaler, S. F. et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 48713\u201348719 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.mcn.2003.12.013","volume":"25","author":"L Pastorino","year":"2004","unstructured":"Pastorino, L. et al. BACE (\u03b2-secretase) modulates the processing of APLP2 in vivo. Mol. Cell Neurosci. 25, 642\u2013649 (2004).","journal-title":"Mol. Cell Neurosci."},{"key":"BFnrd3050_CR62","doi-asserted-by":"publisher","first-page":"17777","DOI":"10.1074\/jbc.M414248200","volume":"280","author":"CA von Arnim","year":"2005","unstructured":"von Arnim, C. A. et al. The low density lipoprotein receptor-related protein (LRP) is a novel \u03b2-secretase (BACE1) substrate. J. Biol. Chem. 280, 17777\u201317785 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR63","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/S0002-9440(10)63419-0","volume":"165","author":"M Willem","year":"2004","unstructured":"Willem, M. et al. \u03b2-Site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am. J. Pathol. 165, 1621\u20131631 (2004).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR64","doi-asserted-by":"publisher","first-page":"23009","DOI":"10.1074\/jbc.M414648200","volume":"280","author":"HK Wong","year":"2005","unstructured":"Wong, H. K. et al. \u03b2 Subunits of voltage-gated sodium channels are novel substrates of \u03b2-site amyloid precursor protein-cleaving enzyme (BACE1) and \u03b3-secretase. J. Biol. Chem. 280, 23009\u201323017 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR65","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11910-009-0054-1","volume":"9","author":"J Neugroschl","year":"2009","unstructured":"Neugroschl, J. & Sano, M. An update on treatment and prevention strategies for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 9, 368\u2013376 (2009).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrd3050_CR66","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.neuron.2008.10.047","volume":"60","author":"T O'Connor","year":"2008","unstructured":"O'Connor, T. et al. Phosphorylation of the translation initiation factor eIF2\u03b1 increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 988\u20131009 (2008).","journal-title":"Neuron"},{"key":"BFnrd3050_CR67","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.neuron.2008.02.024","volume":"57","author":"Y Wen","year":"2008","unstructured":"Wen, Y. et al. Transcriptional regulation of \u03b2-secretase by p25\/cdk5 leads to enhanced amyloidogenic processing. Neuron 57, 680\u2013690 (2008).","journal-title":"Neuron"},{"key":"BFnrd3050_CR68","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1073\/pnas.0710263105","volume":"105","author":"SS Hebert","year":"2008","unstructured":"Hebert, S. S. et al. Loss of microRNA cluster miR-29a\/b-1 in sporadic Alzheimer's disease correlates with increased BACE1\/\u03b2-secretase expression. Proc. Natl Acad. Sci. USA 105, 6415\u20136420 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR69","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1523\/JNEUROSCI.5065-07.2008","volume":"28","author":"WX Wang","year":"2008","unstructured":"Wang, W. X. et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of \u03b2-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213\u20131223 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR70","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nm1784","volume":"14","author":"MA Faghihi","year":"2008","unstructured":"Faghihi, M. A. et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of \u03b2-secretase. Nature Med. 14, 723\u2013730 (2008).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR71","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.neuron.2007.05.012","volume":"54","author":"G Tesco","year":"2007","unstructured":"Tesco, G. et al. Depletion of GGA3 stabilizes BACE and enhances \u03b2-secretase activity. Neuron 54, 721\u2013737 (2007).","journal-title":"Neuron"},{"key":"BFnrd3050_CR72","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nm1088","volume":"10","author":"W He","year":"2004","unstructured":"He, W. et al. Reticulon family members modulate BACE1 activity and amyloid-\u03b2 peptide generation. Nature Med. 10, 959\u2013965 (2004).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR73","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1126\/science.1156609","volume":"320","author":"L Rajendran","year":"2008","unstructured":"Rajendran, L. et al. Efficient inhibition of the Alzheimer's disease \u03b2-secretase by membrane targeting. Science 320, 520\u2013523 (2008).","journal-title":"Science"},{"key":"BFnrd3050_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400, 173\u2013177 (1999). This was the first successful attempt to modify Alzheimer disease plaque pathology using A \u03b2 immunotherapy in an animal model.","journal-title":"Nature"},{"key":"BFnrd3050_CR75","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus, C. et al. A\u03b2 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979\u2013982 (2000).","journal-title":"Nature"},{"key":"BFnrd3050_CR76","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan, D. et al. A\u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982\u2013985 (2000).","journal-title":"Nature"},{"key":"BFnrd3050_CR77","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9440(10)61715-4","volume":"159","author":"EM Sigurdsson","year":"2001","unstructured":"Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B. & Wisniewski, T. Immunization with a nontoxic\/nonfibrillar amyloid-\u03b2 homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439\u2013447 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR78","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nature Med. 6, 916\u2013919 (2000).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR79","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos, R. B. et al. Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850\u20138855 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR80","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. & Holtzman, D. M. Brain to plasma amyloid-\u03b2 efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264\u20132267 (2002).","journal-title":"Science"},{"key":"BFnrd3050_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain A\u03b2 burden in Alzheimer's disease model. Nature Neurosci. 5, 452\u2013457 (2002).","journal-title":"Nature Neurosci."},{"key":"BFnrd3050_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1474-4422(02)00023-6","volume":"1","author":"K Senior","year":"2002","unstructured":"Senior, K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1, 3 (2002). This Phase II study was the first attempt to treat Alzheimer's disease in humans with a disease-modifying therapy.","journal-title":"Lancet Neurol."},{"key":"BFnrd3050_CR83","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman, S. et al. Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).","journal-title":"Neurology"},{"key":"BFnrd3050_CR84","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"RC Dodel","year":"2004","unstructured":"Dodel, R. C. et al. Intravenous immunoglobulins containing antibodies against \u03b2-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472\u20131474 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrd3050_CR85","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","volume":"30","author":"NR Relkin","year":"2008","unstructured":"Relkin, N. R. et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728\u20131736 (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3050_CR86","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484\u2013486 (2001).","journal-title":"Science"},{"key":"BFnrd3050_CR87","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk, D. Amyloid-\u03b2 immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev. Neurosci. 3, 824\u2013828 (2002).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrd3050_CR88","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1371\/journal.pmed.0020355","volume":"2","author":"JL Jankowsky","year":"2005","unstructured":"Jankowsky, J. L. et al. Persistent amyloidosis following suppression of A\u03b2 production in a transgenic model of Alzheimer disease. PLoS Med. 2, e355 (2005).","journal-title":"PLoS Med."},{"key":"BFnrd3050_CR89","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.1073\/pnas.85.18.6617","volume":"85","author":"R Gabizon","year":"1988","unstructured":"Gabizon, R., McKinley, M. P., Groth, D. & Prusiner, S. B. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl Acad. Sci. USA 85, 6617\u20136621 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR90","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0022-510X(82)90155-1","volume":"56","author":"GK Wilcock","year":"1982","unstructured":"Wilcock, G. K. & Esiri, M. M. Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci. 56, 343\u2013356 (1982).","journal-title":"J. Neurol. Sci."},{"key":"BFnrd3050_CR91","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.1074\/jbc.270.16.9564","volume":"270","author":"MB Podlisny","year":"1995","unstructured":"Podlisny, M. B. et al. Aggregation of secreted amyloid \u03b2-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270, 9564\u20139570 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR92","doi-asserted-by":"publisher","first-page":"10831","DOI":"10.1021\/bi001048s","volume":"39","author":"DM Walsh","year":"2000","unstructured":"Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B. & Selkoe, D. J. The oligomerization of amyloid \u03b2-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831\u201310839 (2000).","journal-title":"Biochemistry"},{"key":"BFnrd3050_CR93","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong, Y. et al. Alzheimer's disease-affected brain: presence of oligomeric A \u03b2 ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA 100, 10417\u201310422 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR94","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature04533","volume":"440","author":"S Lesne","year":"2006","unstructured":"Lesne, S. et al. A specific amyloid-\u03b2 protein assembly in the brain impairs memory. Nature 440, 352\u2013357 (2006).","journal-title":"Nature"},{"key":"BFnrd3050_CR95","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nm1423","volume":"12","author":"J McLaurin","year":"2006","unstructured":"McLaurin, J. et al. Cyclohexanehexol inhibitors of A\u03b2 aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature Med. 12, 801\u2013808 (2006).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR96","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar, G. M. et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Med. 14, 837\u2013842 (2008).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR97","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1042\/BST0331087","volume":"33","author":"DM Walsh","year":"2005","unstructured":"Walsh, D. M. et al. The role of cell-derived oligomers of A\u03b2 in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 33, 1087\u20131090 (2005).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd3050_CR98","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1523\/JNEUROSCI.1071-09.2009","volume":"29","author":"QL Ma","year":"2009","unstructured":"Ma, Q. L. et al. \u03b2-Amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078\u20139089 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR99","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","volume":"62","author":"S Li","year":"2009","unstructured":"Li, S. et al. Soluble oligomers of amyloid b protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788\u2013801 (2009).","journal-title":"Neuron"},{"issue":"5","key":"BFnrd3050_CR100","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.neurobiolaging.2009.05.012","volume":"32","author":"Wayne W. Poon","year":"2011","unstructured":"Poon, W. W. et al. \u03b2-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 18 Jun 2009 (doi: 10.1016\/j.neurobiolaging.2009.05.012).","journal-title":"Neurobiology of Aging"},{"key":"BFnrd3050_CR101","doi-asserted-by":"publisher","first-page":"18742","DOI":"10.1074\/jbc.M109.011015","volume":"284","author":"WQ Zhao","year":"2009","unstructured":"Zhao, W. Q. et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A\u03b2. J. Biol. Chem. 284, 18742\u201318753 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR102","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1073\/pnas.0809158106","volume":"106","author":"FG De Felice","year":"2009","unstructured":"De Felice, F. G. et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A\u03b2 oligomers. Proc. Natl Acad. Sci. USA 106, 1971\u20131976 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR103","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0076-6879(06)13017-7","volume":"413","author":"R Kayed","year":"2006","unstructured":"Kayed, R. & Glabe, C. G. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 413, 326\u2013344 (2006).","journal-title":"Methods Enzymol."},{"key":"BFnrd3050_CR104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)64700-1","volume":"156","author":"GK Gouras","year":"2000","unstructured":"Gouras, G. K. et al. Intraneuronal A\u03b242 accumulation in human brain. Am. J. Pathol. 156, 15\u201320 (2000).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR105","doi-asserted-by":"publisher","first-page":"36180","DOI":"10.1074\/jbc.M604436200","volume":"281","author":"CV Zerbinatti","year":"2006","unstructured":"Zerbinatti, C. V. et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal A\u03b242 accumulation in amyloid model mice. J. Biol. Chem. 281, 36180\u201336186 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR106","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1523\/JNEUROSCI.2292-09.2009","volume":"29","author":"D Tampellini","year":"2009","unstructured":"Tampellini, D. et al. Synaptic activity reduces intraneuronal A\u03b2, promotes APP transport to synapses, and protects against A\u03b2-related synaptic alterations. J. Neurosci. 29, 9704\u20139713 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR107","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2202-9-109","volume":"9","author":"B Spencer","year":"2008","unstructured":"Spencer, B. et al. Long-term neprilysin gene transfer is associated with reduced levels of intracellular A\u03b2 and behavioral improvement in APP transgenic mice. BMC Neurosci. 9, 109 (2008).","journal-title":"BMC Neurosci."},{"key":"BFnrd3050_CR108","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2007.09.005","volume":"28","author":"M Arbel","year":"2007","unstructured":"Arbel, M. & Solomon, B. Immunotherapy for Alzheimer's disease: attacking amyloid-\u03b2 from the inside. Trends Immunol. 28, 511\u2013513 (2007).","journal-title":"Trends Immunol."},{"key":"BFnrd3050_CR109","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1523\/JNEUROSCI.1150-09.2009","volume":"29","author":"M Kitazawa","year":"2009","unstructured":"Kitazawa, M., Vasilevko, V., Cribbs, D. H. & LaFerla, F. M. Immunization with amyloid-\u03b2 attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J. Neurosci. 29, 6132\u20136141 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrd3050_CR110","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2353\/ajpath.2009.090044","volume":"175","author":"BM Wegenast-Braun","year":"2009","unstructured":"Wegenast-Braun, B. M. et al. Independent effects of intra- and extracellular A\u03b2 on learning-related gene expression. Am. J. Pathol. 175, 271\u2013282 (2009).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev.pathmechdis.3.121806.154326","volume":"3","author":"A Aguzzi","year":"2008","unstructured":"Aguzzi, A., Sigurdson, C. & Heikenwaelder, M. Molecular mechanisms of prion pathogenesis. Annu. Rev. Pathol. 3, 11\u201340 (2008).","journal-title":"Annu. Rev. Pathol."},{"key":"BFnrd3050_CR112","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/459924a","volume":"459","author":"A Aguzzi","year":"2009","unstructured":"Aguzzi, A. Cell biology: Beyond the prion principle. Nature 459, 924\u2013925 (2009).","journal-title":"Nature"},{"key":"BFnrd3050_CR113","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/37789","volume":"390","author":"MA Klein","year":"1997","unstructured":"Klein, M. A. et al. A crucial role for B cells in neuroinvasive scrapie. Nature 390, 687\u2013690 (1997).","journal-title":"Nature"},{"key":"BFnrd3050_CR114","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/86567","volume":"7","author":"MA Klein","year":"2001","unstructured":"Klein, M. A. et al. Complement facilitates early prion pathogenesis. Nature Med. 7, 488\u2013492 (2001).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR115","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nature02072","volume":"425","author":"M Prinz","year":"2003","unstructured":"Prinz, M. et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425, 957\u2013962 (2003).","journal-title":"Nature"},{"key":"BFnrd3050_CR116","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1073\/pnas.022626399","volume":"99","author":"M Prinz","year":"2002","unstructured":"Prinz, M. et al. Lymph nodal prion replication and neuroinvasion in mice devoid of follicular dendritic cells. Proc. Natl Acad. Sci. USA 99, 919\u2013924 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR117","doi-asserted-by":"publisher","first-page":"e7160","DOI":"10.1371\/journal.pone.0007160","volume":"4","author":"J Bremer","year":"2009","unstructured":"Bremer, J. et al. Repetitive immunization enhances the susceptibility of mice to peripherally administered prions. PLoS One 4, e7160 (2009).","journal-title":"PLoS One"},{"key":"BFnrd3050_CR118","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1086\/595791","volume":"199","author":"CJ Sigurdson","year":"2009","unstructured":"Sigurdson, C. J. et al. Bacterial colitis increases susceptibility to oral prion disease. J. Infect. Dis. 199, 243\u2013252 (2009).","journal-title":"J. Infect. Dis."},{"key":"BFnrd3050_CR119","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nm1105-1137","volume":"11","author":"C Ligios","year":"2005","unstructured":"Ligios, C. et al. PrPSc in mammary glands of sheep affected by scrapie and mastitis. Nature Med. 11, 1137\u20131138 (2005).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR120","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1126\/science.1106460","volume":"307","author":"M Heikenwalder","year":"2005","unstructured":"Heikenwalder, M. et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 307, 1107\u20131110 (2005).","journal-title":"Science"},{"key":"BFnrd3050_CR121","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.embor.embor731","volume":"4","author":"M Prinz","year":"2003","unstructured":"Prinz, M. et al. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep. 4, 195\u2013199 (2003).","journal-title":"EMBO Rep."},{"key":"BFnrd3050_CR122","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nm1177","volume":"11","author":"FL Heppner","year":"2005","unstructured":"Heppner, F. L. et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nature Med. 11, 146\u2013152 (2005).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR123","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri1437","volume":"4","author":"A Aguzzi","year":"2004","unstructured":"Aguzzi, A. & Sigurdson, C. J. Antiprion immunotherapy: to suppress or to stimulate? Nature Rev. Immunol. 4, 725\u2013736 (2004).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrd3050_CR124","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1126\/science.288.5469.1257","volume":"288","author":"F Montrasio","year":"2000","unstructured":"Montrasio, F. et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288, 1257\u20131259 (2000). This was the first successful attempt to block peripheral prion replication pharmacologically in an animal model.","journal-title":"Science"},{"key":"BFnrd3050_CR125","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2008.10.014","volume":"29","author":"M Heikenwalder","year":"2008","unstructured":"Heikenwalder, M. et al. Lymphotoxin-dependent prion replication in inflammatory stromal cells of granulomas. Immunity 29, 998\u20131008 (2008).","journal-title":"Immunity"},{"key":"BFnrd3050_CR126","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.febslet.2009.06.014","volume":"583","author":"M Nuvolone","year":"2009","unstructured":"Nuvolone, M., Aguzzi, A. & Heikenwalder, M. Cells and prions: a license to replicate. FEBS Lett. 583, 2674\u20132684 (2009).","journal-title":"FEBS Lett."},{"key":"BFnrd3050_CR127","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","volume":"161","author":"EM Sigurdsson","year":"2002","unstructured":"Sigurdsson, E. M. et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13\u201317 (2002).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR128","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1016\/j.vaccine.2004.11.067","volume":"23","author":"G Magri","year":"2005","unstructured":"Magri, G. et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 23, 2862\u20132868 (2005).","journal-title":"Vaccine"},{"key":"BFnrd3050_CR129","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1073\/pnas.0404772101","volume":"101","author":"M Polymenidou","year":"2004","unstructured":"Polymenidou, M. et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA 101, 14670\u201314676 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR130","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0304-3940(02)01192-8","volume":"336","author":"EM Sigurdsson","year":"2003","unstructured":"Sigurdsson, E. M. et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336, 185\u2013187 (2003).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3050_CR131","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/1521-4141(200108)31:8<2338::AID-IMMU2338>3.0.CO;2-V","volume":"31","author":"L Souan","year":"2001","unstructured":"Souan, L. et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31, 2338\u20132346 (2001).","journal-title":"Eur. J. Immunol."},{"key":"BFnrd3050_CR132","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1126\/science.1063093","volume":"294","author":"FL Heppner","year":"2001","unstructured":"Heppner, F. L. et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178\u2013182 (2001). This was the first demonstration that the course of prion disease could be significantly altered by PrP antibodies.","journal-title":"Science"},{"key":"BFnrd3050_CR133","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nature01457","volume":"422","author":"AR White","year":"2003","unstructured":"White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80\u201383 (2003).","journal-title":"Nature"},{"key":"BFnrd3050_CR134","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1126\/science.1094273","volume":"303","author":"L Solforosi","year":"2004","unstructured":"Solforosi, L. et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514\u20131516 (2004).","journal-title":"Science"},{"key":"BFnrd3050_CR135","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/brain\/awl150","volume":"129","author":"CR Trevitt","year":"2006","unstructured":"Trevitt, C. R. & Collinge, J. A systematic review of prion therapeutics in experimental models. Brain 129, 2241\u20132265 (2006).","journal-title":"Brain"},{"key":"BFnrd3050_CR136","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1073\/pnas.0902640106","volume":"106","author":"SE Kolstoe","year":"2009","unstructured":"Kolstoe, S. E. et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl Acad. Sci. USA 106, 7619\u20137623 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR137","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1128\/jvi.74.10.4894-4897.2000","volume":"74","author":"K Doh-Ura","year":"2000","unstructured":"Doh-Ura, K., Iwaki, T. & Caughey, B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74, 4894\u20134897 (2000).","journal-title":"J. Virol."},{"key":"BFnrd3050_CR138","doi-asserted-by":"publisher","first-page":"9836","DOI":"10.1073\/pnas.161274798","volume":"98","author":"C Korth","year":"2001","unstructured":"Korth, C., May, B. C., Cohen, F. E. & Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl Acad. Sci. USA 98, 9836\u20139841 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR139","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.LAB.0000074919.08232.A2","volume":"83","author":"C Ryou","year":"2003","unstructured":"Ryou, C. et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab. Invest. 83, 837\u2013843 (2003).","journal-title":"Lab. Invest."},{"key":"BFnrd3050_CR140","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1128\/JVI.78.10.4999-5006.2004","volume":"78","author":"K Doh-Ura","year":"2004","unstructured":"Doh-Ura, K. et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78, 4999\u20135006 (2004).","journal-title":"J. Virol."},{"key":"BFnrd3050_CR141","doi-asserted-by":"publisher","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","volume":"77","author":"A Barret","year":"2003","unstructured":"Barret, A. et al. Evaluation of quinacrine treatment for prion diseases. J. Virol. 77, 8462\u20138469 (2003).","journal-title":"J. Virol."},{"key":"BFnrd3050_CR142","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge, J. et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 8, 334\u2013344 (2009). This was the first anti-aggregation compound to be tested for efficacy in the treatment of prion disease in humans.","journal-title":"Lancet Neurol."},{"key":"BFnrd3050_CR143","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1073\/pnas.97.11.6073","volume":"97","author":"V Perrier","year":"2000","unstructured":"Perrier, V. et al. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc. Natl Acad. Sci. USA 97, 6073\u20136078 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR144","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1021\/jm050610f","volume":"49","author":"TR Reddy","year":"2006","unstructured":"Reddy, T. R. et al. Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. J. Med. Chem. 49, 607\u2013615 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnrd3050_CR145","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(99)11419-3","volume":"355","author":"C Soto","year":"2000","unstructured":"Soto, C. et al. Reversion of prion protein conformational changes by synthetic \u03b2-sheet breaker peptides. Lancet 355, 192\u2013197 (2000).","journal-title":"Lancet"},{"key":"BFnrd3050_CR146","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0798-822","volume":"4","author":"C Soto","year":"1998","unstructured":"Soto, C. et al. \u03b2-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med. 4, 822\u2013826 (1998).","journal-title":"Nature Med."},{"key":"BFnrd3050_CR147","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0197-4580(96)00112-1","volume":"17","author":"J Ma","year":"1996","unstructured":"Ma, J., Brewer, H. B. Jr., & Potter, H. Alzheimer A\u03b2 neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A \u03b2-related peptides. Neurobiol. Aging 17, 773\u2013780 (1996).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3050_CR148","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254\u2013259 (2002).","journal-title":"Nature"},{"key":"BFnrd3050_CR149","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nmeth1131","volume":"4","author":"CJ Sigurdson","year":"2007","unstructured":"Sigurdson, C. J. et al. Prion strain discrimination using luminescent conjugated polymers. Nature Methods 4, 1023\u20131030 (2007).","journal-title":"Nature Methods"},{"key":"BFnrd3050_CR150","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.2174\/138161208786404155","volume":"14","author":"Y Sekijima","year":"2008","unstructured":"Sekijima, Y., Kelly, J. W. & Ikeda, S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr. Pharm. Des. 14, 3219\u20133230 (2008).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrd3050_CR151","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/379339a0","volume":"379","author":"S Brandner","year":"1996","unstructured":"Brandner, S. et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339\u2013343 (1996).","journal-title":"Nature"},{"key":"BFnrd3050_CR152","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","volume":"302","author":"G Mallucci","year":"2003","unstructured":"Mallucci, G. et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871\u2013874 (2003).","journal-title":"Science"},{"key":"BFnrd3050_CR153","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1126\/science.1110837","volume":"308","author":"B Chesebro","year":"2005","unstructured":"Chesebro, B. et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435\u20131439 (2005).","journal-title":"Science"},{"key":"BFnrd3050_CR154","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"J Lauren","year":"2009","unstructured":"Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-\u03b2 oligomers. Nature 457, 1128\u20131132 (2009).","journal-title":"Nature"},{"key":"BFnrd3050_CR155","first-page":"5384","volume":"14","author":"W Rodgers","year":"1994","unstructured":"Rodgers, W., Crise, B. & Rose, J. K. Signals determining protein tyrosine kinase and glycosyl-phosphatidylinositol-anchored protein targeting to a glycolipid-enriched membrane fraction. Mol. Cell Biol. 14, 5384\u20135391 (1994).","journal-title":"Mol. Cell Biol."},{"key":"BFnrd3050_CR156","doi-asserted-by":"publisher","first-page":"23641","DOI":"10.1074\/jbc.270.40.23641","volume":"270","author":"G Arreaza","year":"1995","unstructured":"Arreaza, G. & Brown, D. A. Sorting and intracellular trafficking of a glycosylphosphatidylinositol-anchored protein and two hybrid transmembrane proteins with the same ectodomain in Madin-Darby canine kidney epithelial cells. J. Biol. Chem. 270, 23641\u201323647 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3050_CR157","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1083\/jcb.141.4.929","volume":"141","author":"T Harder","year":"1998","unstructured":"Harder, T., Scheiffele, P., Verkade, P. & Simons, K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 141, 929\u2013942 (1998).","journal-title":"J. Cell Biol."},{"key":"BFnrd3050_CR158","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1093\/emboj\/cdf398","volume":"21","author":"M Fivaz","year":"2002","unstructured":"Fivaz, M. et al. Differential sorting and fate of endocytosed GPI-anchored proteins. EMBO J. 21, 3989\u20134000 (2002).","journal-title":"EMBO J."},{"key":"BFnrd3050_CR159","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0092-8674(00)81572-X","volume":"93","author":"D Shmerling","year":"1998","unstructured":"Shmerling, D. et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203\u2013214 (1998).","journal-title":"Cell"},{"key":"BFnrd3050_CR160","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.emboj.7601510","volume":"26","author":"F Baumann","year":"2007","unstructured":"Baumann, F. et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J. 26, 538\u2013547 (2007).","journal-title":"EMBO J."},{"key":"BFnrd3050_CR161","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/sj.emboj.7601507","volume":"26","author":"A Li","year":"2007","unstructured":"Li, A. et al. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105\u2013125 EMBO J. 26, 548\u2013558 (2007).","journal-title":"EMBO J."},{"key":"BFnrd3050_CR162","doi-asserted-by":"publisher","first-page":"17342","DOI":"10.1073\/pnas.0506723102","volume":"102","author":"T Luhrs","year":"2005","unstructured":"Luhrs, T. et al. 3D structure of Alzheimer's amyloid-\u03b2(1\u201342) fibrils. Proc. Natl Acad. Sci. USA 102, 17342\u201317347 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3050_CR163","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jneuroim.2007.09.022","volume":"192","author":"M Heikenwalder","year":"2007","unstructured":"Heikenwalder, M. et al. Germinal center B cells are dispensable in prion transport and neuroinvasion. J. Neuroimmunol. 192, 113\u2013123 (2007).","journal-title":"J. Neuroimmunol."},{"key":"BFnrd3050_CR164","doi-asserted-by":"publisher","first-page":"e3308","DOI":"10.1371\/journal.pone.0003308","volume":"3","author":"J Sponarova","year":"2008","unstructured":"Sponarova, J., Nystrom, S. N. & Westermark G. T. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS ONE 3, e3308 (2008).","journal-title":"PLoS ONE"},{"key":"BFnrd3050_CR165","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1128\/JVI.77.12.6845-6854.2003","volume":"77","author":"NA Mabbott","year":"2003","unstructured":"Mabbott, N. A., Young, J., McConnell, I & Bruce, M. E. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J. Virol. 77, 6854\u20136854 (2003).","journal-title":"J. Virol."},{"key":"BFnrd3050_CR166","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2353\/ajpath.2010.080797","volume":"176","author":"KP Nilsson","year":"2010","unstructured":"Nilsson, K. P. et al. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am. J. Pathol. 176, 563\u2013574 (2010).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3050_CR167","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1093\/emboj\/cdg537","volume":"22","author":"C Hetz","year":"2003","unstructured":"Hetz, C. et al. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J. 22, 5435\u20135445 (2003).","journal-title":"EMBO J."},{"key":"BFnrd3050_CR168","volume-title":"Elan website","author":"Elan","year":"2009","unstructured":"Elan. Press Release 8 July 2009: Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting. Elan website [online], = (2009)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrd3050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd3050","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd3050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T14:12:14Z","timestamp":1711289534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":168,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BFnrd3050"],"URL":"https:\/\/doi.org\/10.1038\/nrd3050","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}